

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Paradigm Biopharmaceuticals Limited
ABN	94 169 346 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Paul Rennie
Date of last notice	18 June 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Direct (2) Indirect (3) Indirect (4) Indirect (5) Indirect (6) Direct (7) Indirect
Nature of indirect interest (including registered holder)	(1) N/A (2) SMSF (3) FT (4) SMSF (5) SMSF (6) N/A (7) SMSF
Date of change	(6) 29 June 2026

⁺ See [chapter 19](#) for defined terms.

No. of securities held prior to change	(1.1) 376,470 - FULLY PAID ORDINARY SHARES (1.2) 176,470 - LISTED OPTIONS @ \$0.2375 EXP 01/12/2026 (2.1) 10,944,313 - FULLY PAID ORDINARY SHARES (2.2) 176,470 - LISTED OPTIONS @ \$0.2375 EXP 01/12/2026 (3) 600,000 - FULLY PAID ORDINARY SHARES (4.1) 1,700,000 - PERFORMANCE RIGHTS EXP 20/12/2027 (4.2) 1,500,000 - PERFORMANCE RIGHTS EXP 17/02/2029 (5) 76,633 - UNLISTED PIGGYBACK OPTS @ \$1 EXP 11/02/2028 (6) 8,545,848 - FULLY PAID ORDINARY SHARES (7.1) 942,794 - FULLY PAID ORDINARY SHARES (7.2) 176,470 - LISTED OPTIONS @ \$0.2375 EXP 01/12/2026
Class	(1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPTIONS @ \$0.2375 EXP 01/12/2026 (2.1) FULLY PAID ORDINARY SHARES (2.2) LISTED OPTIONS @ \$0.2375 EXP 01/12/2026 (3) FULLY PAID ORDINARY SHARES (4.1) PERFORMANCE RIGHTS EXP 20/12/2027 (4.2) PERFORMANCE RIGHTS EXP 17/02/2029 (5) UNLISTED PIGGYBACK OPTS @ \$1 EXP 11/02/2028 (6) FULLY PAID ORDINARY SHARES (7.1) FULLY PAID ORDINARY SHARES (7.2) LISTED OPTIONS @ \$0.2375 EXP 01/12/2026
Number acquired	NIL
Number disposed	(6) (600,000 - FULLY PAID ORDINARY SHARES)
Value/Consideration	(6) N/A

No. of securities held after change	(1.1) 376,470 - FULLY PAID ORDINARY SHARES (1.2) 176,470 - LISTED OPTIONS @ \$0.2375 EXP 01/12/2026 (2.1) 10,944,313 - FULLY PAID ORDINARY SHARES (2.2) 176,470 - LISTED OPTIONS @ \$0.2375 EXP 01/12/2026 (3) 600,000 - FULLY PAID ORDINARY SHARES (4.1) 1,700,000 - PERFORMANCE RIGHTS EXP 20/12/2027 (4.2) 1,500,000 - PERFORMANCE RIGHTS EXP 17/02/2029 (5) 76,633 - UNLISTED PIGGYBACK OPTS @ \$1 EXP 11/02/2028 (6) 7,945,848 - FULLY PAID ORDINARY SHARES (7.1) 942,794 - FULLY PAID ORDINARY SHARES (7.2) 176,470 - LISTED OPTIONS @ \$0.2375 EXP 01/12/2026
Nature of change	(6) Lapse of performance shares as employee share scheme not being achieved

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.